Mayne Pharma Group Ltd (ASX:MYX)
A$ 4.58 -0.05 (-1.08%) Market Cap: 389.64 Mil Enterprise Value: 279.18 Mil PE Ratio: 0 PB Ratio: 0.83 GF Score: 75/100

Mayne Pharma Group Ltd at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 03:30PM GMT
Release Date Price: A$5.71 (-3.22%)
Dan Delfico JP Morgan Chase;Co.;Analyst

&-

Good morning, everybody. Welcome to the 42nd Annual JPMorgan Healthcare Conference. My name is Dan Delfico. I'm one of the associates on the banking team here. This morning it's my pleasure to introduce to you Mayne Pharma. With us today we have CEO, Shawn O'Brien, CFO, Aaron Gray, and EVP Commercial, Daniel Moore.

I'm just reminded that at the end of the presentation, there will be a Q&A session. We'll have a mic being passed around. And with that, I'll turn it over to Shawn.

Shawn O Brien
Mayne Pharma Group Ltd - Chief Executive Officer, Managing Director, Executive Director

Thank you, Dan and JPMorgan team for this opportunity to share the main transformation story. We're moving this company from a high capital-intense business to a high growth, high margin business. And as I said, Aaron Gray, our CFO, and Daniel Moore here join me for the Q&A period. On our disclaimer slide I'd just like to bring to your attention that these results are unaudited that I'm sharing with you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot